VBS Pharmaceuticals Targets Vascular‒based Diseases
VBS Pharmaceuticals, a majority owned subsidiary of
Vascular BioSciences, advances targeted therapies in order to improve outcomes for patients with difficult to treat diseases.
VBS Pharmaceuticals, a majority owned subsidiary of
Vascular BioSciences, advances targeted therapies in order to improve outcomes for patients with difficult to treat diseases.